de Bree Godelieve J, Wheatley Adam K, Lynch Rebecca M, Prabhakaran Madhu, Grijsen Marlous L, Prins Jan M, Schmidt Stephen D, Koup Richard A, Mascola John R, McDermott Adrian B
Department of Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Institute for Global Health and Development, University of Amsterdam, Amsterdam, The Netherlands.
PLoS One. 2017 Mar 15;12(3):e0173577. doi: 10.1371/journal.pone.0173577. eCollection 2017.
Neutralizing antibodies develop in natural HIV-1 infection. Their development often takes several years and may rely on chronic virus exposure. At the same time recent studies show that treatment early in infection may provide opportunities for immune preservation. However, it is unknown how intermittent treatment in early infection affects development of the humoral immune response over time. We investigate the effect of cART in early HIV infection on the properties of the memory B cell compartment following 6 months of cART or in the absence of treatment. The patients included participated in the Primo-SHM trial where patients with an early HIV-1 infection were randomized to no treatment or treatment for 24 or 60 weeks.
Primo-SHM trial patients selected for the present study were untreated (n = 23) or treated for 24 weeks (n = 24). Here we investigate memory B cell properties at viral set-point and at a late time point (respectively median 54 and 73 weeks) before (re)-initiation of treatment.
At viral set-point, the memory B cell compartment in treated patients demonstrated significantly lower fractions of antigen-primed, activated, memory B cells (p = 0.006). In contrast to untreated patients, in treated patients the humoral HIV-specific response reached a set point over time. At a transcriptional level, sets of genes that showed enhanced expression in memory B cells at viral setpoint in untreated patients, conversely showed rapid increase of expression of the same genes in treated patients at the late time point.
These data suggest that, although the memory B cell compartment is phenotypically preserved until viral setpoint after treatment interruption, the development of the HIV-specific antibody response may benefit from exposure to HIV. The effect of viral exposure on B cell properties is also reflected by longitudinal changes in transcriptional profile in memory B cells over time in early treated patients.
在自然HIV-1感染过程中会产生中和抗体。其产生通常需要数年时间,且可能依赖于长期的病毒暴露。与此同时,近期研究表明,感染早期进行治疗可能为免疫保护提供机会。然而,早期感染时的间歇性治疗如何随时间影响体液免疫反应的发展尚不清楚。我们研究了在接受6个月抗逆转录病毒治疗(cART)或未接受治疗的情况下,早期HIV感染中cART对记忆B细胞区室特性的影响。纳入的患者参与了Primo-SHM试验,该试验将早期HIV-1感染患者随机分为不治疗组或接受24周或60周治疗组。
本研究选取的Primo-SHM试验患者中,未治疗组(n = 23)或接受24周治疗组(n = 24)。在此,我们研究治疗前(重新)开始治疗时病毒载量设定点以及晚期时间点(分别为中位数54周和73周)的记忆B细胞特性。
在病毒载量设定点时,接受治疗患者的记忆B细胞区室中抗原致敏、活化的记忆B细胞比例显著降低(p = 0.006)。与未治疗患者不同,接受治疗患者的体液HIV特异性反应随时间达到一个稳定水平。在转录水平上,未治疗患者在病毒载量设定点时记忆B细胞中表达增强的基因集,在接受治疗患者的晚期时间点时,这些相同基因的表达则迅速增加。
这些数据表明,尽管记忆B细胞区室在治疗中断后直到病毒载量设定点时在表型上得以保留,但HIV特异性抗体反应的发展可能受益于HIV暴露。早期接受治疗患者记忆B细胞转录谱随时间的纵向变化也反映了病毒暴露对B细胞特性的影响。